Is statin-induced myositis part of the polymyositis disease spectrum?

Current Rheumatology Reports

Volumn 16, Issue 8, 2014, Pages

  Albayda, Jemima ^a   Mammen, Andrew L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Anti HMG CoA reductase; Classification criteria; IMNM; Necrotizing myopathy; Polymyositis; Statin myopathy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNE RESPONSE; MYOPATHY; MYOSITIS; PATHOGENESIS; POLYMYOSITIS; PROTEIN EXPRESSION; TREATMENT INDICATION; UPREGULATION; AUTOIMMUNE DISEASES; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOSITIS; POLYMYOSITIS;

EID: 84905560568     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0433-8     Document Type: Article

References (37)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-7.
3. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337-45. (Pubitemid 38507409)
4. Dalakas M. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med. 1991;325(21):1487-98.
5. Kissel JT, Mendell JR, Rammohan KW. Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis. N Engl J Med. 1986;314(6):329-34. (Pubitemid 16166259)
6. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193-208. (Pubitemid 14062666)
7. Emslie-Smith A, Arahata K, Engel AG. Major histocompatibility complex class 1 antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224-31. (Pubitemid 19081957)
8. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668-74.
9. Linklater H, Pipitone N, Rose M, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol. 2013;31(5):767-9.
10. Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, et al. Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies: Study of 178 Cases and Guidelines for Diagnosis. Medicine (Baltimore). 2013;92(1):15-24.
11. Troyanov Y, Targoff IN, Tremblay J-L, Goulet J-R, Raymond Y, Senecal J-L. Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies: Analysis of 100 French Canadian Patients. Medicine (Baltimore). 2005;84(4):231-49. (Pubitemid 41026298)
12. Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527-35. (Pubitemid 27504210)
13. • Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, et al. Immune-Mediated Necrotizing Myopathy Is Characterized by a Specific Th1-M1 Polarized Immune Profile. Am J Pathol. 2012;181(6):2161-71. This study demonstrated that a difference in cellular and molecular characteristics can distinguish immune-mediated necrotizing myopathies from non-immune-mediated necrotizing myopathies.
14. Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol. 2013;25(6):772-7.
15. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in Polymyositis and Dermatomyositis. Curr Rheumatol Rep [Internet]. 2013. [cited 2014 May 21];15(6). Available from: 10.1007/s11926-013-0335-1
16. Cruellas M, Viana V, Levy-Neto M, Souza F, Shinjo S. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics. 2013;68(7):909-14.
17. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757-66.
18. Tansley S, Gunawardena H. The Evolving Spectrum of Polymyositis and Dermatomyositis - Moving Towards Clinicoserological Syndromes: A Critical Review. Clin Rev Allergy Immunol [Internet]. 2013. [cited 2014 Mar 1]; Available from: http://link.springer.com/10.1007/s12016-013-8387-6
19. Van der Meulen MFG, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: An overdiagnosed entity. Neurology. 2003;61(3):316-21. (Pubitemid 36975958)
20. Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun [Internet]. 2014 [cited 2014 Mar 1]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0896841114000286
21. Harris LJ, Thapa R, Brown M, Pabbathi S, Childress RD, Heimberg M, et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J Clin Lipidol. 2011;5(4): 299-307.
22. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients - The PRIMO Study. Cardiovasc Drugs Ther. 2006;19(6):403-14. (Pubitemid 43228152)
23. Law M, Rudnicka AR. Statin Safety: A Systematic Review. Am J Cardiol. 2006;97(8):S52-60.
24. Graham DJ, Staffa JA, Shatin D, et al. INcidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-90. (Pubitemid 39577514)
25. Mammen A, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22(6):644-50.
26. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8(3): 333-8.
27. SLCO1B1 Variants and Statin-Induced Myopathy - A Genomewide Study. N Engl J Med. 2008;359(8):789-99.
28. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185-90.
29. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHCI associated with statin therapy. Neuromuscul Disord. 2007;17(2): 194-200. (Pubitemid 46274372)
30. Goldman J, Fishman A, Lee J, Johnson R. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum. 1989;32(3):358-9. (Pubitemid 19100426)
31. Schalke B, Schmidt B, Toyka K, Hartung H. Pravastatin-Associated Inflammatory Myopathy. N Engl J Med. 1992;327(9):649-50.
32. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet. 1997;349(9065):1600-1. (Pubitemid 27229143)
33. • Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713-21. This study identified the autoantigen involved in statin-associated autoimmune myopathy and provided a mechanistic link between the drug and development of sustained autoimmunity.
34. • Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64(2):269-72. This study demonstrated that anti-HMGCR is infrequently seen in patients who take statins, including those with self-limited statin intolerance, and is specific for an autoimmune myopathy.
35. • Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1*11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res. 2012;1233-7. This study identified class II HLA loci that confer susceptibility to and protection from anti-HMGCR myopathy.
36. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087-93.
37. Cabot RC, Harris NL, Rosenberg ES, Shepard J-AO, Cort AM, Ebeling SH, et al. Case 37-2012: A 21-Year-Old Man with Fevers, Arthralgias, and Pulmonary Infiltrates. N Engl J Med. 2012;367(22):2134-46.